Research

dna, analysis, research-3539309.jpg

Experiences of mothers of long-term surviving patients with cerebral adrenoleukodystrophy: a qualitative study

Experiences of mothers of long-term surviving patients with cerebral adrenoleukodystrophy: a qualitative study Overview: The study focuses on the lived experiences of mothers caring for long-term survivors of cerebral adrenoleukodystrophy (CALD), a rare genetic disorder affecting the nervous system. It employs qualitative research methods, including in-depth interviews with mothers, to gather rich, personal insights. Key …

Experiences of mothers of long-term surviving patients with cerebral adrenoleukodystrophy: a qualitative study Read More »

dna, analysis, research-3539309.jpg

Gene therapy shows long-term benefit for patients with Cerebral adrenoleukodystrophy (CALD)

Gene therapy shows long-term benefit for patients with Cerebral adrenoleukodystrophy (CALD) Overview: In a study published in The New England Journal of Medicine, lentiviral gene therapy using elivaldogene autotemcel (eli-cel) showed promising results in treating cerebral adrenoleukodystrophy (CALD) in boys. Over a 24-month period, 91% of participants survived without major functional disabilities, and 94% showed …

Gene therapy shows long-term benefit for patients with Cerebral adrenoleukodystrophy (CALD) Read More »

dna, analysis, research-3539309.jpg

Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD

Reductions in Very Long-Chain Fatty Acids and Plasma Lipid Levels Observed After 28 Days of Once Daily Dosing 

VK0214 Shown to be Safe and Well-Tolerated in 28-Day Study

SAN DIEGO, Oct. 9, 2024 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive data from the company’s Phase 1b clinical trial of VK0214, a novel small molecule agonist of the thyroid hormone receptor beta (TRβ), in patients with X-linked adrenoleukodystrophy (X-ALD).  Results from this study showed VK0214 to be safe and well-tolerated following once-daily dosing over the 28-day study period. In addition, significant reductions were observed in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.

dna, analysis, research-3539309.jpg

BridgeBio Shares Positive Data from Canavan Disease Study

BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 –Continued, progressive improvement in motor function and achievement of motor milestones at 12-months post-treatment represents an important and statistically significant change, in contrast to the disease course observed in BridgeBio’s ongoing CANinform …

BridgeBio Shares Positive Data from Canavan Disease Study Read More »